Shares of Nektar Therapeutics are down 31.4% at $2.03 per share afterhours after the company provided Phase 2 data on rezpegaldesleukin in lupus. The company had stated that while the mid-dose level demonstrated a numeric improvement in SLEDAI-2K score as compared to placebo, the primary endpoint was not met.
Published first on TheFly
See today’s best-performing stocks on TipRanks >>
Read More on NKTR:
